Subscribe: Market Wire - Pharmaceuticals and Biotech: Biotech
Added By: Feedage Forager Feedage Grade B rated
Language: English
announced  announces  cannabis  company  feb  february  marketwired feb  marketwired february  marketwired  new  otcqb  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Biotech

Marketwired - Biotech

Marketwired - Biotech

Last Build Date: Mon, 27 Feb 2017 09:09:06 EST

Copyright: Copyright: (C) Marketwired

Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

Mon, 27 Feb 2017 09:00:00 EST

LOS ANGELES, CA--(Marketwired - Feb 27, 2017) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results for the fourth quarter and full year ended December 31, 2016.

Amedica Announces Results of Independent Femoral Head Wear Testing

Mon, 27 Feb 2017 09:00:00 EST

SALT LAKE CITY, UT--(Marketwired - Feb 27, 2017) - Amedica Corporation (NASDAQ: AMDA), an innovative biomaterial company which develops and manufactures silicon nitride as a platform for biomedical applications, announced today that Researchers from the Department of Orthopaedic Surgery of Tokyo Medical University (Shinjuku-ku, Tokyo, Japan) led by Professor Kengo Yamamoto MD PhD recently completed a five million cycle (Mc) comparative hip simulator study examining the wear behavior of an advanced highly cross-linked and vitamin E stabilized polyethylene (E1® Zimmer-Biomet, Warsaw, IN, USA) against two different types of ceramic femoral heads -- MC2®silicon nitride (Amedica Corporation, Salt Lake City, UT, USA) and BIOLOX®delta (CeramTec, Plochingen, Germany). BIOLOX®delta is currently considered the "gold standard" for ceramic femoral head materials. While the polyethylene wear loss induced by both types of ceramic heads was extremely small (< 0.60 mg/Mc), mean wear associated with MC2®silicon nitride heads was approximately 15% lower than the BIOLOX®delta components.

BriaCell CEO Equity Investment Advances Company's Lead Cancer Product and Pipeline Expansion

Mon, 27 Feb 2017 08:30:00 EST

BERKELEY, CA and VANCOUVER, BC --(Marketwired - February 27, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) announced today that its President and CEO, Dr. William Williams has entered into a non-brokered private placement (the "Offering") of 5,416,667 units of the Company (the "Units") at a price of C$0.24 per Unit for aggregate gross proceeds of C$1,300,000. Under the terms of the Offering, each Unit shall consist of one common share in the capital of the Company (a "Common Share") and one-half of a Common Share purchase warrant (a "Warrant"). Each Warrant will be exercisable for one Common Share at an exercise price of C$0.35. The Warrants will be exercisable for 24 months following the date of closing of the Offering. The Offering is subject to the approval of the TSX Venture Exchange and other customary closing conditions.

ORYZON presented new preclinical data of ORY-2001 therapeutic activity in Multiple Sclerosis at ACTRIMS-2017

Mon, 27 Feb 2017 08:00:00 EST

ORY-2001 Reduces Lymphocyte Egress and Demyelination in Experimental Autoimmune Encephalomyelitis; Data highlights the Epigenetic Axis in Multiple Sclerosis

Lion Biotechnologies to Present at Upcoming Investor Conferences in March

Mon, 27 Feb 2017 08:00:00 EST

SAN CARLOS, CA--(Marketwired - February 27, 2017) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, announced today that company management will present a corporate update at two investor conferences in March:

Aevi Genomic Medicine to Present at the Cowen and Company 37th Annual Health Care Conference

Mon, 27 Feb 2017 08:00:00 EST

PHILADELPHIA, PA--(Marketwired - Feb 27, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA on Monday, March 6, 2016 at 4:40 p.m. EST at the Boston Marriott Copley Place.

Lexaria Receives Notice of its First Patent to be Granted in Australia for Cannabinoid Infused Edibles

Mon, 27 Feb 2017 08:00:00 EST

KELOWNA, BC--(Marketwired - February 27, 2017) - Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") is pleased to announce it has received a Notice of Acceptance from the Australian Patent Office that Lexaria's Australian patent application 2015274698 has been accepted with a patent issuance date expected in June, 2017. This establishes Lexaria's first successful acceptance for patent issuance outside of the USA, in what the Company expects will be a series of successful international patent awards.

Pieris Signs 1st Partnership for Anemia Drug PRS-080, Granting Exclusive Option in Japan to ASKA Pharmaceutical

Mon, 27 Feb 2017 07:30:00 EST

Novel Hepcidin Inhibitor Addressing High Medical Need in Anemia of Chronic Disease

Helix BioPharma Corp. Announces Licence for Worldwide Right to Anti-CEACAM6 Antibody From the Government of Canada

Mon, 27 Feb 2017 07:30:00 EST

TORONTO, ON--(Marketwired - Feb 27, 2017) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that it has completed a licence agreement with the National Research Council of Canada ("NRC") for the worldwide right to anti-CEACAM6 antibody 2A3 for oncology applications.

RepliCel Life Sciences Announces Closing of Brokered and Non-brokered Private Placement

Fri, 24 Feb 2017 15:41:12 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 24, 2017) -

ORYZON Reports Financial Results and Corporate Update for the Fourth Quarter and Year Ended December 31, 2016

Fri, 24 Feb 2017 13:40:04 EST

BARCELONA, SPAIN and CAMBRIDGE, MA--(Marketwired - February 24, 2017) - Oryzon Genomics (MAD: ORY) (ISIN Code: ES0167733015), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the fourth quarter of 2016 and provided an update on the Company's recent developments.

Trillium Therapeutics Provides Additional Details on ASCO-SITC Conference Presentation on TTI-621

Fri, 24 Feb 2017 11:30:00 EST

TTI-621's Half-life and Receptor Occupancy Significantly Increased with Weekly Dosing

Cannabis Science Announces Update on Proposed DPI Inhalation Device, CBD Infused Pain Patch, and Extends Praise for President Trump's Support of Medical Cannabis, Nationwide

Fri, 24 Feb 2017 11:06:27 EST

IRVINE, CA--(Marketwired - Feb 24, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce updates on the proposed self-medicating DPI Inhalation Device for Asthma/COPD and our Cannabinoid infused pain patch. The Company is working on the final packaging for the Cannabinoid-based Pain Patches and will roll out to partner dispensaries in the Los Angeles area very soon, joining the existing Cannabis Science product line.

Medifirst Solutions Updates Shareholders

Fri, 24 Feb 2017 11:00:00 EST

FREEHOLD, NJ--(Marketwired - Feb 24, 2017) -  MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the "Company" or "Medifirst") would like to update shareholders in order to follow up on its Time Machine Conference in Morocco, as well as to provide recent Company developments regarding its FDA cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device.

Planting tomorrow's trees today; climate change is threatening the health of Canada's forests, but revolutionary genomics research will give foresters a way to push back

Fri, 24 Feb 2017 11:00:00 EST

VANCOUVER, BC--(Marketwired - February 24, 2017) - Traditional methods for reforestation use seeds from local tree populations. With the climate quickly changing, these local trees will be poorly adapted to new environments that not only have warmer temperatures, but also more disease pressures. And climate change isn't just bad for trees. It's also bad for the economic and environmental benefits they provide to Canada -- benefits like wood, jobs, habitat protection and carbon sequestration.

Theratechnologies tiendra une conférence web destinée aux investisseurs le 1er mars 2017

Fri, 24 Feb 2017 10:06:35 EST

MONTRÉAL, QUÉBEC--(Marketwired - 24 fév. 2017) - Theratechnologies Inc. (TSX:TH) (Theratechnologies) a annoncé aujourd'hui qu'elle tiendra une conférence web destinée aux investisseurs le 1er mars 2017. Celle-ci débutera à 9 heures (heure normale de l'est) et devrait se terminer vers 11 heures (heure normale de l'est).

Theratechnologies to Host Investment Community Webcast on March 1, 2017

Fri, 24 Feb 2017 10:05:29 EST

MONTREAL, QUEBEC--(Marketwired - Feb. 24, 2017) - Theratechnologies Inc. (TSX:TH) (Theratechnologies) announced today that it will host an Investment Community Webcast on March 1, 2017, at 9:00 a.m. (Eastern Standard Time), and should conclude at approximately 11:00 a.m. (Eastern Standard Time).

The Webcast will be hosted by Luc Tanguay, President and Chief Executive Officer, and will also feature presentations by Philippe Dubuc, Senior Vice President and Chief Financial Officer, Christian Marsolais, Senior Vice President and Chief Medical Officer, and Lyne Fortin, Senior Vice President and Chief Commercial Officer. Theratechnologies intends to provide detailed information on its growth strategy, particularly regarding its ibalizumab commercial launch preparation, as well as provide updated 2017 financial guidance. The Webcast will provide an opportunity for both investors and analysts to ask questions about the company's activities.

ALGAE DYNAMICS CORP Announces Research Agreement With University of Waterloo to Investigate Use of Cannabis Oil in the Context of Cancer

Fri, 24 Feb 2017 09:30:00 EST

TORONTO, ON--(Marketwired - Feb 24, 2017) - ALGAE DYNAMICS CORP (OTCQB: ADYNF) (the "Company"), a development stage company focused on the commercialization of its proprietary BioSilo® cultivation and extraction system for the growth of algae strains for use in the food and health supplement industry, today announced a research agreement with the University of Waterloo to perform fundamental research on cannabis oil and its constituents in the context of the development and treatment of cancers of the colorectum, pancreas, breast and prostate. The Sponsored Research Agreement is entitled "Studies on botanical oils from Algae Dynamics".

Canadian Cannabis Task Force Cites Impaired Driving as a Serious Issue Demanding Immediate Attention -- CFN Media

Fri, 24 Feb 2017 09:02:28 EST

SEATTLE, WA--(Marketwired - Feb 24, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an article discussing the Canadian Cannabis Task Force's recommendations for addressing impaired driving, and Cannabix Technologies' (OTC PINK: BLOZF) position in the emerging cannabis breathalyzer market.

SANUWAVE Receives U.S. Patent for a Special Construction of Shock Wave Electrodes and the Method to Adjust Their Spark Gap

Fri, 24 Feb 2017 09:00:00 EST

SUWANEE, GA--(Marketwired - Feb 24, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company patent number 9,566,209 titled "Shock Wave Electrodes with Fluid Holes" that has an expiration date on June 21, 2033. This patent relates to a new construction of the spark gap electrodes used to generate acoustic pressure shock waves in SANUWAVE's devices, which allows a longer useful life for the applicators. The twenty (20) claims of the patent cover the construction of the acoustic pressure shock wave applicators that incorporate such electrodes and methods to adjust the spark gap distance in between the electrodes using calculation of equivalent capacitance of the applicator's head.

EnWave Announces 2017 First Quarter Consolidated Interim Financial Results

Fri, 24 Feb 2017 09:00:00 EST

VANCOUVER, BC--(Marketwired - February 24, 2017) - EnWave Corporation (TSX VENTURE: ENW) (FRANKFURT: E4U) ("EnWave", or the "Company") today reported the Company's consolidated interim financial results for the first quarter ended December 31, 2016. The Company reported consolidated revenue of $3,467,000, and a consolidated net loss of $618,000 for the first quarter of fiscal year 2017.

Tetra Bio-Pharma Grants Stock Options

Fri, 24 Feb 2017 08:30:00 EST

OTTAWA, ONTARIO--(Marketwired - Feb. 24, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF) announces that on February 23, 2017, in accordance with the Company's stock option plan and subject to the approval of the Canadian Securities Exchange, the Board of Directors granted an aggregate of 750,000 incentive stock options ("options") to its officers and directors of the Company. Each option, vesting immediately upon grant, entitles the holder thereof to purchase one common share in the capital of the Company at a price of $0.70 per share until February 23, 2022. The options and any common shares issued upon exercise thereof will be subject to a four month resale restriction from the date of grant.

Quadron Signs LOI to Acquire Automation Design Firm With Expertise In the Cannabis Sector, Cybernetics

Fri, 24 Feb 2017 08:30:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 24, 2017) - Quadron Capital Corp. (the "Company" or "Quadron") - (CSE:QCC) - is pleased to announce that it has entered into a letter of intent (the "LOI") to acquire all of the issued and outstanding securities of Cybernetics Control Systems Inc. ("Cybernetics"), an arm's length party, (the "Acquisition").

First Half 2017 Operational Update

Fri, 24 Feb 2017 02:13:12 EST

SYDNEY, AUSTRALIA--(Marketwired - Feb 24, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)

A Federal Crackdown on Recreational Cannabis Could Cost Industry Billions and Thousands of Jobs

Thu, 23 Feb 2017 18:07:12 EST

WASHINGTON, DC--(Marketwired - February 23, 2017) - New Frontier Data, the authority in business intelligence for the cannabis industry, for the past two years has been monitoring the top 10 trends that could affect the market and a cannabis unfriendly administration has been among those. Today White House Press Secretary Sean Spicer suggested that those on the recreational side of the industry could see "greater enforcement" from the Department of Justice. If the federal government decided to crack down on the adult use side, this year alone, it could jeopardize $2.5 billion in projected revenue and $8.6 billion by 2020.

Bio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results

Thu, 23 Feb 2017 16:26:43 EST

HERCULES, CA--(Marketwired - Feb 23, 2017) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2016.

CloudHealth Genomics Presents their Unique Market Strategy and ImmuneSeq(TM) Panel for both Cancer and Non-Cancer Immunotherapies

Thu, 23 Feb 2017 14:06:03 EST

BOSTON, MA and SHANGHAI, CHINA--(Marketwired - Feb 23, 2017) - CloudHealth Genomics, Ltd., a leading genomics-based precision medicine solutions provider in China, presented data today on their unique business model, using open and disruptive innovation as a market strategy for precision medicine, wellness and longevity. In addition, data was presented as a by-product of the model, ImmuneSeq panel at the Cambridge Healthtech Institute's Third Annual Commercialization of Molecular Diagnostics, part of the 24th International Molecular Medicine Tri-Conference held in San Francisco, CA. ImmuneSeq is able to monitor immune responses, like T-cell activities for both cancer and non-cancer immunotherapies. ?Becomes First ELK HIPAA-Compliant Log Analytics Platform

Thu, 23 Feb 2017 13:30:00 EST Helps Healthcare IT departments analyze log data to detect anomalies, prevent failures, and protect patient information

iData Research Publishes Article on U.S. Orthopedic Biomaterials Market: Shift in Competitive Strategy

Thu, 23 Feb 2017 13:20:51 EST

Cellular allografts currently comprise the fastest growing segment of the orthopedic biomaterials market in the U.S.; the high average selling price of cellular allografts provides incentives for new players to enter the market

Ogilvy CommonHealth Worldwide's Michael Zilligen to speak at the Advertising and Promotion Regulatory Affairs Conference

Thu, 23 Feb 2017 12:15:42 EST

PARSIPPANY, NJ--(Marketwired - Feb 23, 2017) - Ogilvy CommonHealth Worldwide (, the health behavior change specialists of Ogilvy & Mather (, and a WPP Health & Wellness company (NASDAQ: WPPGY) (, today announced Michael Zilligen, president of Ogilvy CommonHealth Payer Marketing and Ogilvy Healthworld Payer Marketing, has been selected to speak at the Advertising and Promotion Regulatory Affairs Conference taking place February 23 and 24 in Washington, DC.

Ogilvy CommonHealth Worldwide's Baranello and Vidal Inducted Into the Medical Advertising Hall of Fame's Future Famers Program

Thu, 23 Feb 2017 09:46:54 EST

PARSIPPANY, NJ--(Marketwired - Feb 23, 2017) -  Ogilvy CommonHealth Worldwide (, the health behavior change specialists of Ogilvy & Mather (, and a WPP Health & Wellness company (NASDAQ: WPPGY) (, today announced Jigna Baranello, VP, account group supervisor, and Ana Maria Vidal, account executive, were both named to the Medical Advertising Hall of Fame's (MAHF) fifth annual Future Famers Program at last night's awards dinner held at the Pierre Hotel in New York City.

First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals

Thu, 23 Feb 2017 09:15:00 EST

NEW YORK, NY--(Marketwired - February 23, 2017) - PharmaCyte Biotech (OTCQB: PMCB) will join GW Pharmaceuticals, Abbott Laboratories and 66 other publicly traded companies in what could be the first ever cannabis exchange-traded fund (ETF) -- the Emerging AgroSphere ETF. One week ago, ETF Managers Group, headquartered in Summit, New Jersey, filed an initial registration statement with the SEC to become the first of its kind in the ETF industry (

The Life Sciences Report Examines How the RXi-MirImmune Merger Is Aiming to Unlock Value Through Groundbreaking Technology

Thu, 23 Feb 2017 09:00:00 EST

SAN FRANCISCO, CA--(Marketwired - February 23, 2017) - RXi Pharmaceuticals Corp.'s (NASDAQ: RXII) proprietary self-delivering RNAi (sd-rxRNA) platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It's no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. In this interview with The Life Sciences Report, Geert Cauwenbergh, RXi's President and CEO; Alexey Eliseev, Chief Business Officer; and Pam Pavco, Chief Development Officer, discuss their technologies, the merger and why they believe that in 10 years pure chemotherapy could be relegated to the treatment of last resort.

SANUWAVE Health, Inc. Launches "SHOCK THIS" Blog

Thu, 23 Feb 2017 09:00:00 EST

SUWANEE, GA--(Marketwired - Feb 23, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV) announces the launch of the blog, SHOCK THIS on its website The initial post will be from SANUWAVE's head of Research and Development, Dr. Iulian Cioanta, titled "What is a shockwave." The goal of the blog is to allow a medium to help educate customers, patients, partners, and the public about the various initiatives under way at SANUWAVE. The blog will also accept posts and comments (approved by SANUWAVE), which the Company views as valuable to the SANUWAVE community. This is expected to be a constructive forum for users from around the globe. By having a central location, SHOCK THIS, the Company can bring together in one setting various information that will be useful and entertaining to the SANUWAVE community. The initial blog is meant to help people understand, what is a shock wave. Many misconceptions exist about the technology, what it is and what it isn't, so the plan is to help expand people's understanding by educating in a fun manner. Members of the SANUWAVE community are encouraged to interact and reach out with thoughts and ideas, which will positively impact the SANUWAVE community as a whole. SANUWAVE Health, Inc. reserves the right to edit or exclude comments it deems not positively impacting the experience or is not appropriate from legal and regulatory perspectives. Kevin Richardson, SANUWAVE's Acting CEO, said, "This is an exciting launch for us as SANUWAVE begins the process of educating the market on the Company's technology and devices' capabilities. In the hopes of receiving FDA approval in the future, this is a first step in building SANUWAVE brand awareness."

Golden Leaf Launches New Golden Gold Label Reserve Product Line

Thu, 23 Feb 2017 08:30:00 EST

TORONTO, ON--(Marketwired - February 23, 2017) - Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE: GLH) (OTCQB: GLDFF), a leading cannabis oil solutions company built around recognized brands, is pleased to announce the introduction of its new Golden Gold Label Reserve product line, new Private Stash brand strain flavors, and branded Golden full flower pre-roll joints. Launching in dispensaries across Oregon, Gold Label Reserve and the new Private Stash strain varieties are targeted at medical and recreational customers looking for pure solvent-free and high potency cannabis oil products. The Golden pre-roll joints focus on meeting growing consumer demand for high quality pre-rolled joints.

Arch Biopartners Announces TSXV Stock Ticker Symbol Change to "ARCH"

Thu, 23 Feb 2017 08:15:00 EST

TORONTO, ONTARIO--(Marketwired - Feb. 23, 2017) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) a portfolio based biotechnology company, announced today that the Company's common shares will begin trading under the new stock ticker symbol "ARCH" on the TSX Venture Exchange (TSXV), effective at the open of trading on February 24, 2017.

Corbus Pharmaceuticals Announces Preclinical Data Demonstrating JBT-101 Reduces Inflammation in Alveolar Macrophages from Cystic Fibrosis Patients

Thu, 23 Feb 2017 08:05:00 EST

Alveolar Macrophages treated with JBT-101 demonstrated reduced levels of key pro-inflammatory cytokines, TNF- alpha and IL-6

Webinar to Help Assess Your Compliance Readiness: Tips for DSCSA Implementation - Faster, Easier and Done Right

Thu, 23 Feb 2017 07:30:00 EST

TORONTO, ON--(Marketwired - February 23, 2017) - On Wednesday, March 15, 2017, Xtalks will host a complimentary webinar featuring guest speakers from Verify Brand including Tim Donelon, Director of Quality and Validation, Haris Kamal, Senior Vice President, and Scott Pugh, Solution Architect.

MapR Joins Susan G. Komen(R) in the Mission to end Breast Cancer

Thu, 23 Feb 2017 07:00:00 EST

SAN JOSE, CA--(Marketwired - Feb 23, 2017) - MapR Technologies, Inc., the provider of the first and only converged data platform, is advising Susan G. Komen as the breast cancer organization convenes its second national conference with subject matter experts working to leverage Big Data for breast cancer care.

Cleveland BioLabs Reports 2016 Financial Results and Development Progress

Wed, 22 Feb 2017 16:15:00 EST

BUFFALO, NY--(Marketwired - Feb 22, 2017) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and year ended December 31, 2016.

Pegasystems to Present at Upcoming Investor Conferences

Wed, 22 Feb 2017 16:05:00 EST

CAMBRIDGE, MA--(Marketwired - February 22, 2017) - Pegasystems Inc. (NASDAQ: PEGA), the software company empowering customer engagement at the world's leading enterprises, today announced its participation in the following investor conferences:

Preparing for ICH-GCP E6(R2) at Investigator Sites, New Xtalks Webinar Presented by Intralinks

Wed, 22 Feb 2017 15:39:53 EST

Live Session on March 15, 2017 Includes Q&A with GCP Inspector and Discussion on Investigator Site Perspectives

Aeolus Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers

Wed, 22 Feb 2017 15:13:29 EST

MISSION VIEJO, CA--(Marketwired - February 22, 2017) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection, announced today the initiation of a phase 1 study with its lead compound AEOL 10150. The phase 1 study is an open-label, single center, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of an escalating single dose of AEOL 10150 administered by subcutaneous injection in healthy subjects.

Fresenius Lead Dialysis Machine Market Fueled by Popularity of Home-Hemodialysis Treatment

Wed, 22 Feb 2017 14:00:00 EST

The market for hemodialysis machines is comprised of in-center machines and home hemodialysis machines; the market will exceed a value of $360 million by 2023

Présentation de Neptune à la 29e conférence annuelle Growth Stock de ROTH Capital Partners

Wed, 22 Feb 2017 13:54:58 EST

LAVAL, QUÉBEC--(Marketwired - 22 fév. 2017) - Neptune Technologies & Bioressources inc. (« Neptune » ou la « Société ») (NASDAQ:NEPT)(TSX:NEPT) a annoncé que Jim Hamilton, son président et chef de la direction, donnera une présentation le lundi 13 mars à 14 h 30 (HP) dans le cadre de la 29e conférence annuelle ROTH qui se tiendra au Ritz-Carlton de Laguna Niguel, en Californie. Pour en savoir plus ou pour planifier une rencontre individuelle avec un membre de la direction, veuillez communiquer avec votre représentant ROTH au 1-800-933-6830 ou par courriel à

Neptune to Present at ROTH Capital Partners 29th Annual Growth Stock Conference

Wed, 22 Feb 2017 13:54:13 EST

LAVAL, QUÉBEC--(Marketwired - Feb. 22, 2017) - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (NASDAQ:NEPT)(TSX:NEPT), announced that Jim Hamilton, CEO of the Corporation, will present at the 29th Annual ROTH Conference at the Ritz-Carlton, Laguna Niguel, CA on Monday, March 13 at 2:30pm PT. For more information about the conference or to schedule a one-on-one meeting with management, please contact your ROTH representative at 1-800-933-6830 or via e-mail

Harvest One Announces Closing of $25 Million Financing Related to Acquisition of ACMPR Licensed Medical Cannabis Producer and Swiss Medical Cannabis-Based Health Products Company

Wed, 22 Feb 2017 12:06:42 EST

TORONTO, ONTARIO--(Marketwired - Feb. 22, 2017) -

Ogilvy CommonHealth Worldwide's Nora Tsivgas to present at the 8th Hub and SPP Model Optimization Event

Wed, 22 Feb 2017 11:14:36 EST

PARSIPPANY, NJ--(Marketwired - Feb 22, 2017) - Ogilvy CommonHealth Worldwide (, the health behavior change specialists of Ogilvy & Mather (, and a WPP Health & Wellness company (NASDAQ: WPPGY) (, today announced Nora Tsivgas, SVP, access services strategies at Ogilvy CommonHealth Payer Marketing, will lead a workshop during the Hub and SPP Model Optimization conference in Philadelphia, PA, on Thursday, February, 23.

Prolacta Bioscience(R) to Present at the Cowen and Company 37th Annual Health Care Conference on March 7th, 2017

Wed, 22 Feb 2017 09:05:00 EST

DUARTE, CA--(Marketwired - Feb 22, 2017) - Prolacta Bioscience® -- the nation's leading provider of human milk-based neonatal nutritional products, announced today that it will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. Scott Elster, Prolacta's President and Chief Executive Officer, is scheduled to present on Tuesday, March 7, 2017 at 2:30 PM EST.

eWellness to Present at the 2017 Wall Street Conference in Boca Raton on March 1, 2017

Wed, 22 Feb 2017 08:50:00 EST

CULVER CITY, CA--(Marketwired - Feb 22, 2017) - eWellness Healthcare Corporation, (OTCQB: EWLL) is the first telehealth company for physical therapy to offer insurance reimbursable remotely monitored physical therapy (PT) treatments. The Company will be presenting at the Wall Street Conference in Boca Raton Florida at 10:00am March 1, 2017.

New Frontier Data: U.S. Cannabis Market Creates 283,422 Jobs by 2020

Wed, 22 Feb 2017 08:38:32 EST

WASHINGTON, DC--(Marketwired - February 22, 2017) - New Frontier Data, the authority in business intelligence for the cannabis industry, continues to find evidence demonstrating the legal cannabis is one of the fastest growing industries in the U.S., and examines its growth in its upcoming annual report, The Cannabis Industry Annual Report: 2017 Legal Marijuana Outlook. New Frontier Data projects that by 2020 the legal cannabis market will create more than a quarter million jobs for American workers.

Eco Science Solutions, Inc. Verified to Trade on OTCQB

Wed, 22 Feb 2017 08:30:00 EST

MAUI, HI--(Marketwired - Feb 22, 2017) - Eco Science Solutions, Inc. (OTCBB: ESSI), an eco-technology Company providing solutions to the multi-billion dollar health, wellness and alternative medicine industry, today announced that it has been verified to trade on the OTCQB Venture Market.

Global Small Caps Initiates Coverage on Nutra Pharma

Wed, 22 Feb 2017 08:30:00 EST

CORAL SPRINGS, FL--(Marketwired - Feb 22, 2017) - Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company developing drugs for the treatment of Multiple Sclerosis and HIV that also markets Nyloxin® and Pet Pain-AwayT in the over-the-counter (OTC) pain management market, announced today that Global Small Caps has initiated coverage of the Company including operations and overall shareholder value.

Sipp Industries in Partnership with Sleeping Giant Brewing Embarks on Formulation of New Cannabidiol Infused Beer

Wed, 22 Feb 2017 08:30:00 EST

As Sales for "Major Hemp Brown Ale" Take Off, Company Prepares for Second Quarter Launch of Next Select Premium Brewing Innovation

VBI Vaccines Receives Positive Response from Health Canada's Initial Evaluation of the Proposed Sci-B-Vac Phase III Clinical Program

Wed, 22 Feb 2017 08:30:00 EST

CAMBRIDGE, MASSACHUSETTS--(Marketwired - Feb. 22, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") announced today that the Biologics and Genetic Therapies Directorate (BGTD) of Health Canada expressed its general support and acceptance of the company's development path for its Sci-B-VacT vaccine, a prophylactic vaccine against hepatitis B, in a pre-Clinical Trial Application ("CTA") meeting. A complete CTA must be filed with and approved by BGTD, and all conditions of BGTD must be met, prior to the initiation of a clinical program in Canada.

Apexian Pharmaceutical CEO, Steve Carchedi, to present at Drexel University's Guest Healthcare Lecture Series

Wed, 22 Feb 2017 08:04:05 EST

PHILADELPHIA, PA--(Marketwired - February 22, 2017) - Apexian Pharmaceuticals, a clinical stage biotechnology company focused on developing novel compounds to treat cancer, today announced that its CEO would present at Drexel University's Healthcare Guest Lecture Series ( to be held at Gerri C. LeBow Hall (GHall), room 722, 3220 Market St, Philadelphia, PA 19104 on the campus of Drexel University at 4:30 PM EST on March 1, 2017.

BioVie Submits Additional Information to FDA for BIV201 Clinical Trial in Ascites Patients

Wed, 22 Feb 2017 08:00:00 EST

BEVERLY, MA--(Marketwired - February 22, 2017) - BioVie Inc. (OTC PINK: BIVI), a development-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, announced today that it has submitted a complete response to the U.S. Food and Drug Administration (FDA) addressing the issues identified in the Investigational New Drug Application (IND) clinical hold letter received by BioVie last month.

Aldeyra Therapeutics Launches the Aldeyra Registry for Patients with Sjögren-Larsson Syndrome

Wed, 22 Feb 2017 08:00:00 EST

LEXINGTON, MA--(Marketwired - Feb 22, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it has developed and launched the Aldeyra Registry for Sjögren-Larsson Syndrome (SLS), a rare inborn error of aldehyde metabolism that is characterized by severe skin and neurological disease. The Aldeyra Registry for SLS is designed to unite SLS patients worldwide, and to raise awareness of the significant physical challenges associated with the disease.

NuGene International Appoints S. David Ollie As Vice President, Sales

Wed, 22 Feb 2017 08:00:00 EST

Veteran Sales Executive in both Medical and Aesthetic areas of Dermatology and Plastic Surgery Industries

Zenosense, Inc.: MIDS Quantitative Testing Commences

Wed, 22 Feb 2017 08:00:00 EST

VALENCIA, SPAIN--(Marketwired - Feb 22, 2017) - Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS CardiacT, a Point of Care ("POC") handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected acute myocardial infarction (heart attack), is pleased to announce that MIDS Medical Limited ("MML"), our joint venture based at Sci-Tech, Daresbury, has completed construction of two bench readers designed to test two methods of magnetic nanoparticle detection.

Vinergy Resources/MJ BioPharma to Acquire 65% of Health Canada and FDA Licensed Laboratory to Pursue Drug Testing and Dosage of CBDs, THC and Terpenes

Wed, 22 Feb 2017 08:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 22, 2017) - Vinergy Resources Ltd. ("Vinergy" or the "Company") (CSE:VIN)(OTCQB:VNNYF) in conjunction with its proposed acquisition of MJ BioPharma (announced December 14, 2016) is pleased to announce that, as a part of the Company's strategy to develop products that test and identify specific cannabinoid isolates for targeted therapeutic purposes it has signed a binding Letter of Intent ("LOI") to acquire 65% of Biolennia Laboratories Inc. (the "Laboratory").

30% of Drug Companies Compensate HCPs Differently for International vs. Domestic Air Travel

Wed, 22 Feb 2017 07:48:00 EST

Pharma Companies Establish FMV Travel Policies for Healthcare Providers

Adgero Biopharmaceuticals Holdings Inc. Announces $2.0 Million Investment from Strategic Asian Investor

Wed, 22 Feb 2017 07:30:00 EST

PRINCETON, NJ--(Marketwired - February 22, 2017) - Adgero Biopharmaceuticals Holdings, Inc. ("Adgero" or the "Company"), a privately-held biopharmaceutical company leveraging its late stage photodynamic therapy ("PDT") platform for the treatment of serious oncology indications, announced today that it has received a $2.0 million investment from Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. ("FDZJ"), located in Shanghai, China.

30Mil CAD$ Investment in European Centre of Cancer Immunotherapy

Wed, 22 Feb 2017 07:30:00 EST

TORONTO, ON--(Marketwired - Feb 22, 2017) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that Helix Immuno-Oncology ("HIO") has signed a non-binding letter of intent with KEN Poland Limited Liability Partnership ("KEN POLAND") in support of the European Centre for Cancer Immunotherapy ("ECCI").

NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016

Wed, 22 Feb 2017 07:00:00 EST

Migration of all Clarient Clients to NeoGenomics Lab Information System Now Complete

InCrowd Debuts MicroQual, First Qualitative Micro Research Solution for Life Sciences & Healthcare

Wed, 22 Feb 2017 07:00:00 EST

By Allowing Completion of Healthcare Stakeholder Interviews in a Fraction of the Time, MicroQual Delivers Richer, More Comprehensive Market Insights, Sourced with Validated Experts

Revive Therapeutics Announces Term Sheet with InMed Pharmaceuticals for the Discovery and Development of Cannabinoid-Based Therapy Targeting Kidney Diseases

Wed, 22 Feb 2017 07:00:00 EST

TORONTO, ONTARIO--(Marketwired - Feb. 22, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), today announced the Company has entered into a term sheet agreement with InMed Pharmaceuticals Inc. ("InMed") for the discovery and development of cannabinoid-based therapies targeting kidney diseases.

Southwest Cannabis Conference & Expo Returns to Texas for Largest Event Yet

Wed, 22 Feb 2017 06:00:00 EST

DALLAS, TX--(Marketwired - Feb 22, 2017) - The Southwest Cannabis Conference & Expo ( is returning to Texas for its second annual event. After setting new records at the last event in Phoenix -- where more than 150 exhibitors showcased their goods to over 6,800 attendees -- the SWCC Expo is looking to set new records in 2017.

Model N to Present Global Pricing and Tendering Strategies at Pharma Pricing and Market Access Congress 2017

Wed, 22 Feb 2017 03:00:00 EST

Join Model N to learn industry trends and best practices for optimal global pricing

SafetyChain Software's February FSMA Fridays Session to Focus on Listeria Guidance from FDA

Tue, 21 Feb 2017 17:43:38 EST

SAN RAFAEL, CA--(Marketwired - February 21, 2017) - SafetyChain Software, the leading innovator of food safety & quality management solutions, is pleased to announce the February 2017 topic for its popular FSMA Fridays series with Dr. David Acheson and The Acheson Group team - Listeria Guidance from the FDA.

Aevi Genomic Medicine Announces Expansion of its Collaboration with The Children's Hospital of Philadelphia

Tue, 21 Feb 2017 17:27:25 EST

PHILADELPHIA, PA--(Marketwired - Feb 21, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that it has strengthened its discovery and research platform by extending its genomics collaboration with the Center for Applied Genomics (CAG) at Children's Hospital of Philadelphia (CHOP). The amendment to the existing agreement with CHOP grants the Company options for long-term exclusive access to certain data and samples from the CAG biobank and certain discoveries in rare and orphan diseases. Aevi Genomics has also renewed its Sponsored Research Agreement (SRA) with CHOP. The extension of the SRA marks the third renewal of sponsored research at CHOP, jointly focused on the genetics of rare and orphan pediatric disease. 

BioAegis Therapeutics Announces Addition of Leading Critical Care Nephrologist to its Clinical Advisory Board

Tue, 21 Feb 2017 13:01:44 EST

Markers of Acute Kidney Injury to be Monitored in Forthcoming Clinical Trials

hVIVO notes the initiation of a Phase I clinical trial with AGS-v, a mosquito-borne disease vaccine candidate

Tue, 21 Feb 2017 12:28:10 EST

Vaccine could protect against diseases such as Zika and Malaria; hVIVO's joint venture investment with SEEK in a new company, Imutex, was formed to accelerate the development of this vaccine

AssistRx to Offer its iAssist Solution on the Accenture Intelligent Patient Service Exchange

Tue, 21 Feb 2017 11:30:00 EST

ORLANDO, FL--(Marketwired - Feb 21, 2017) - AssistRx (ARx), the leading enterprise technology platform focused on specialty and highly managed medications, today announced it will make available its iAssist solution on the Accenture Intelligent Patient Service Exchange, a digital marketplace of third-party technology solutions available to life sciences companies to enhance patient support and improve the overall patient treatment experience.

Taglich Brothers Initiates Coverage on Aytu Bioscience, Inc.

Tue, 21 Feb 2017 10:04:43 EST

NEW YORK, NY--(Marketwired - February 21, 2017) - Taglich Brothers, Inc. announces it initiated coverage of AYTU Bioscience, Inc.

tranSMART Foundation Announces Version 16.2 - A Collaborative Effort of the tranSMART Community

Tue, 21 Feb 2017 10:00:54 EST

SAN FRANCISCO, CA and WAKEFIELD, MA--(Marketwired - Feb 21, 2017) - (Molecular Med Tri-Conference, booth #423) The tranSMART Foundation, a non-profit organization providing a global, open-source, open-data knowledge management platform for scientists to share pre-competitive translational research data, today announced the newest release of its tranSMART platform, version 16.2. This version includes significant contributions from numerous members of the tranSMART community and provides users with more advanced functionality to enhance their translational research studies.

Advantis Corp. Begins Distribution of Ground Breaking New Cannabis Products for Pain Relief

Tue, 21 Feb 2017 09:37:30 EST

NEWPORT BEACH, CA--(Marketwired - Feb 21, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) begins distribution of topical cannabis roll-on and Tinctures to treat pain conditions.

Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer

Tue, 21 Feb 2017 09:05:00 EST

CITY OF INDUSTRY, CA--(Marketwired - Feb 21, 2017) - Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced the appointment of Seymour Fein, M.D., as Chief Medical Officer

SANUWAVE Announces Hiring of Andre Mouton as VP of International Sales and Relations

Tue, 21 Feb 2017 09:00:00 EST

SUWANEE, GA--(Marketwired - Feb 21, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce the hiring of André Mouton to head the Company's international sales and relations. SANUWAVE began a process 18 months ago of re-igniting their international efforts. This meant re-designing distribution agreements, restructuring partner economics, letting go of certain distributors, and adding new partners. The Company has also installed applicator refurbishment centers closer to the regions where the device is being used and this has had a strong acceptance among SANUWAVE's customers. As SANUWAVE grows and expands on a country by country basis, the Company has found three models which work well for us: Distribution, Joint Ventures, and Exclusive Rights Agreements. Since the Company's refocus on international sales the number of countries actively served has grown from 3 to 10, the number of device placements has tripled, and sales have increased as well. 

Pegasystems Brings Concierge-Level Service To Digital Experiences With Launch of Pega Self-Service Advisor

Tue, 21 Feb 2017 09:00:00 EST

First AI-powered capability to sense customer intent and deliver tailored customer service to existing web and mobile channels

Avadim Technologies Inc.'s Newest Board Member, Humberto C. Antunes, Earns Lifetime Achievement Award

Tue, 21 Feb 2017 09:00:00 EST

Recognized for his Decades of Contributions Toward the Advancement of Dermatology and Aesthetics

FMV Budget is a Top Criterion Among Surveyed Companies When Evaluating IIT Proposals

Tue, 21 Feb 2017 08:36:00 EST

RESEARCH TRIANGLE PARK, NC--(Marketwired - February 21, 2017) - Nearly one-third of surveyed pharmaceutical companies look to fair-market value (FMV) budget as one their most important criteria for evaluating investigator initiated trial (IIT) proposals, according to a study by business intelligence firm Cutting Edge Information.

Arch Biopartners Announces Non-Brokered Private Placement Financing

Tue, 21 Feb 2017 08:30:00 EST

TORONTO, ONTARIO--(Marketwired - Feb. 21, 2017) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) a portfolio based biotechnology company, intends to complete a non-brokered private placement offering of up to 1,000,000 common shares priced at $0.40 per common share (the "Common Shares") for gross proceeds of up to $400,000 (the "Offering"). All Common Shares issued in connection with the Offering will be subject to a hold period of four months and one day from the closing date.

Easton Pharmaceuticals / BMV Medica Announces Successful Product Sales Launch Conference Of Product Gynofit and Additional Distribution of Product AL-Sense (AmnioSense) With Multi-National Pharmaceutical Company Gedeon Richter

Tue, 21 Feb 2017 08:00:00 EST

TORONTO, ON--(Marketwired - Feb 21, 2017) - Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) and partner, BMV Medica SA, announce successful product launch of "Gynofit" and further announce final stage agreement with multi-national Gedeon Richter for the distribution of Easton / BMV's AL-Sense (AmnioSense) product.

CannaRoyalty to Begin Trading Today on OTCQB Marketplace

Tue, 21 Feb 2017 07:56:53 EST

OTTAWA, ONTARIO--(Marketwired - Feb. 21, 2017) - CannaRoyalty Corp. (CSE:CRZ)(CSE:CRZ.CN)(OTCQB:CNNRF) ("CannaRoyalty" or the "Company") is pleased to announce that it has received approval for trading on the OTCQB Venture Market ("OTCQB"). The Company commences trading under the symbol "CNNRF" at market open today on the OTCQB.

Soricimed Publishes the Results of Phase I Study of SOR-C13 in Patients with Advanced Solid Tumors

Tue, 21 Feb 2017 07:30:00 EST

TORONTO, ONTARIO--(Marketwired - Feb. 21, 2017) - Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company discovering and developing peptide-based cancer therapeutics, is pleased to announce publication of their paper entitled, First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. This peer-reviewed paper was published in the journal Investigational New Drugs, The Journal of New Anticancer Agents. This open-access publication can be viewed online at

MediXall Group, Inc. Announces Strategic Agreement with Renaissance Health System of Florida, Inc.

Tue, 21 Feb 2017 07:30:00 EST

FT. LAUDERDALE, FL--(Marketwired - Feb 21, 2017) - MediXall Group Inc. (OTCQB: MDXL) is a technology and innovation-driven organization structured to bring effective change to the U.S. healthcare industry.

Soricimed publie les résultats d'une étude de phase I du SOR-C13 chez les patients atteints de tumeurs solides avancées

Tue, 21 Feb 2017 07:30:00 EST

TORONTO, ONTARIO--(Marketwired - 21 fév. 2017) - Soricimed Biopharma Inc. (« Soricimed »), une compagnie pharmaceutique au stade clinique spécialisée dans la recherche et la mise au point de thérapies contre le cancer à partir de peptides, est heureuse d'annoncer la publication de l'article intitulé First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors (première étude de phase 1, chez l'humain, du SOR-C13, un inhibiteur des canaux calciques TRPV6, chez des patients présentant des tumeurs solides avancées). Cet article soumis à un comité de lecture a été publié dans la revue Investigational New Drugs, The Journal of New Anticancer Agents. Cette publication en libre accès peut être consultée sur le

Corbus Pharmaceuticals to Host Research and Development Day on March 13, 2017

Tue, 21 Feb 2017 07:30:00 EST

Updates on clinical development of JBT-101 and presentation of new pre-clinical and MOA data; Live video webcast on March 13th from 11:00 AM to 1:00 PM ET

Applied DNA Sciences Expands Patent Portfolio with a Range of Advancements that Enable Company's Continued Penetration of Core Business Verticals

Tue, 21 Feb 2017 05:30:00 EST

New patents applicable to a broad range of markets, including pharmaceuticals and industrial products, among others

Vernalis PLC: Unaudited Interim Results for the six months ended 31 December 2016

Tue, 21 Feb 2017 02:00:00 EST

WINNERSH, UNITED KINGDOM--(Marketwired - Feb 21, 2017) - Vernalis PLC (LSE: VER)

ORYZON to present ORY-2001 new preclinical data of therapeutic activity at ACTRIMS-2017 in Orlando, Fl. USA

Mon, 20 Feb 2017 09:29:47 EST

The company will present a poster on February 24th 2017